Apr 4 |
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug
|
Apr 3 |
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
|
Apr 3 |
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
|
Apr 3 |
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
|
Apr 3 |
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
|
Apr 2 |
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
|
Apr 2 |
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
|
Apr 2 |
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
|
Apr 2 |
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
|
Apr 1 |
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
|